Wilms’ tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives

References

• van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254(5038):1643–9. doi:10.1126/science.1840703.
   PubMed Web of Science ®Google Scholar
• Lee MY, Jeon JW, Sievers C, Allen CT. Antigen processing and presentation in cancer immunotherapy. J Immunother Cancer. 2020;8(2):e001111. doi:10.1136/jitc-2020-001111.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004;10(9):909–15. doi:10.1038/nm1100.
   PubMed Web of Science ®Google Scholar
• Sugiyama H. WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010;40(5):377–87. doi:10.1093/jjco/hyp194.
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19(6):804–14. doi:10.1038/modpathol.3800588.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101(38):13885–90. doi:10.1073/pnas.0405884101.
   PubMed Web of Science ®Google Scholar
• Nishida S, Ishikawa T, Egawa S, Koido S, Yanagimoto H, Ishii J, Kanno Y, Kokura S, Yasuda H, Saito-Oba M, et al. Combination gemcitabine and WT1 peptide vaccination improves progression-free survival in advanced pancreatic ductal adenocarcinoma: a phase II randomized study. Cancer Immunol Res. 2018;6(3):320–31. doi:10.1158/2326-6066.CIR-17-0386.
   PubMed Web of Science ®Google Scholar
• Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, et al. WT1 (Wilms’ tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol. 2007;51(5):519–30. doi:10.1111/j.1348-0421.2007.tb03940.x.
   PubMed Web of Science ®Google Scholar
• Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shrakata T, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. JNS. 2008;108(5):963–71. doi:10.3171/JNS/2008/108/5/0963.
   PubMed Web of Science ®Google Scholar
• Nishida S, Morimoto S, Oji Y, Morita S, Shrakata T, Enomoto T, Tsuboi A, Ueda Y, Yoshino K, Shouq A, et al. Cellular and humoral immune responses induced by an HLA class I–restricted peptide cancer vaccine targeting WT1 are associated with favorable clinical outcomes in advanced ovarian cancer. J Immunother. 2022;45(1):56–66. doi:10.1097/CJI.0000000000000405.
   PubMed Web of Science ®Google Scholar
• Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, et al. WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies. Int J Cancer. 2018;142(11):2375–82. doi:10.1002/ijc.31253.
   PubMed Web of Science ®Google Scholar
• Nakajima H, Nakata J, Imafuku K, Hayashibara H, Isokawa K, Udaka K, Fujiki F, Morimoto S, Hasegawa K, Hosen N, et al. Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunol Immunother. 2021;70(11):3323–3335. doi:10.1007/s00262-021-03003-5.
   PubMed Web of Science ®Google Scholar
• Nakata J, Nakajima H, Hayashibara H, Imafuku K, Morimoto S, Fujiki F, Motooka D, Okuzaki D, Hasegaewa K, Hosen N, et al. Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides. Oncotarget. 2018;9(89):36029–38. doi:10.18632/oncotarget.26338.
   PubMedGoogle Scholar
• Tsuboi A, Hashimoto N, Fujiki F, Morimoto S, Kagawa N, Nakajima H, Hosen N, Nishida S, Nakata J, Morita S, et al. A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma. Cancer Immunol Immunother. 2019;68(2):331–340. doi:10.1007/s00262-018-2274-1.
   PubMed Web of Science ®Google Scholar
• Oj Y, Kagawa N, Arita H, Naka N, Hamada K, Outani H, Shintani Y, Takeda Y, Morii E, Shimazu K, et al. WT1 trio peptide-based cancer vaccine for rare cancers expressing shared target WT1. Cancers Basel. 2023;15(2):393. doi:10.3390/cancers15020393.
   PubMed Web of Science ®Google Scholar
• Manning-Geist BL, Gnjatic S, Aghajanian C, Konner J, Kim SH, Sarasohn D, Soldan K, Tew WP, Sarlis NJ, Zamarin D, et al. Phase I study of multivalent WT1 peptide vaccine (galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission. Cancers (Barsel). 2023;15(5):1458. doi:10.3390/cancers15051458.
   PubMed Web of Science ®Google Scholar
• Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, Elisseeva OA, Harada Y, Ito K, Li Z, et al. Identification and characterization of a WT1 (Wilms tumor gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother. 2007;30(3):282–93. doi:10.1097/01.cji.0000211337.91513.94.
   PubMed Web of Science ®Google Scholar
• Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I, Hato T, Takahashi M, Senju S, Nishimura Y, et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood. 2005;106(4):1415–18. doi:10.1182/blood-2005-01-0413.
   PubMed Web of Science ®Google Scholar
• May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA. Peptide epitopes from the Wilms’ tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13(15):4547–55. doi:10.1158/1078-0432.CCR-07-0708.
   PubMed Web of Science ®Google Scholar
• Knight AJ, Zaniou A, Rees RC, Pawelec G, Muller L. Prediction of an HLA-DR-binding peptide derived from Wilms’ tumor 1 protein and demonstration of in vitro immunogenicity of WT1 (124-138)-pulsed dendritic cells generated according to an optimized protocol. Cancer Immunol Immunother. 2002;51(5):271–81. doi:10.1007/s00262-002-0278-2.
   PubMed Web of Science ®Google Scholar
• Fujiki F, Tsuboi A, Morimoto S, Hashimoto N, Inatome M, Nakajima H, Nakata J, Nishida S, Hasegawa K, Hosen N, et al. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides. Cancer Immunol Immunother. 2021;70(1):253–263. doi:10.1007/s00262-020-02675-9.
   PubMed Web of Science ®Google Scholar
• Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. doi:10.1038/s41577-019-0210-z.
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257–67. doi:10.1016/S1470-2045(13)70585-0.
   PubMed Web of Science ®Google Scholar
• Zhang W, Lu X, Cui P, Piao C, Xiao M, Liu X, Wang Y, Wu X, Liu J, Yang L. PaseI/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer. Caner Immunol Immunother. 2019;68(1):121–30. doi:10.1007/s00262-018-2257-2.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.012.
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Phase I/II study of Wilms’ tumor 1 peptide-pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer. Ther Apher Dial. 2019;23(3):279–88. doi:10.1111/1744-9987.12831.
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer. Ther Apher Dial. 2020;24(5):482–491. doi:10.1111/1744-9987.13542.
   PubMed Web of Science ®Google Scholar
• Ota S, Miyashita M, Yamagishi Y, Ogasawara M. Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy. Hum Vaccin Immunother. 2021;17(12):5563–5572. doi:10.1080/21645515.2021.2003645.
   PubMed Web of Science ®Google Scholar
• Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)–specific MHC class I/II–restricted epitopes for pancreatic cancer. Clin Cancer Res. 2014;20(16):4228–39. doi:10.1158/1078-0432.CCR-14-0314.
   PubMed Web of Science ®Google Scholar
• Nagai K, Adachi T, Harada H, Eguchi S, Sugiyama H, Miyazaki Y. Dendritic cell-based immunotherapy pulsed with Wilms tumor 1 peptide and mucin 1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a phase I/IIa clinical trial. Anticancer Res. 2020;40(10):5765–5776. doi:10.21873/anticanres.14593.
   PubMed Web of Science ®Google Scholar
• Keilholtz U, Letsch A, Busse A, Asemissen M, Bauer S, Blau IW, Hofmann W-K, Uharek L, Thiel E, Scheibenbogen C. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26):6541–8. doi:10.1182/blood-2009-02-202598.
   PubMed Web of Science ®Google Scholar
• Nakata J, Nakae Y, Kawakami M, Morimoto S, Motooka D, Hosen N, Fujiki F, Nakajima H, Hasegawa K, Nishida S, et al. Wilms tumor 1 peptide vaccine as a cure-oriented post-chemotherapy strategy for patients with acute myeloid leukemia at high risk of relapse. Br J Haematol. 2018;182(2):287–90. doi:10.1111/bjh.14768.
   PubMed Web of Science ®Google Scholar
• Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2018;2(3):224–34. doi:10.1182/bloodadvances.2017014175.
   PubMed Web of Science ®Google Scholar
• Anguille S, Van de Velde AL, Smit EL, Van Tendeloo VF, Juliusson G, Cools N, Nijs G, Stein B, Lion E, Van Driesshe A, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017;130(15):1713–21. doi:10.1182/blood-2017-04-780155.
   PubMed Web of Science ®Google Scholar
• Jamy OH, Khan SS, Tsirigotis P, Tomlinson BK, Hunault-Berger M, Platzbecker U, Sakellari I, Vidovic A, Montesinos P, Del Castillo TB, et al. A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator’s choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy. J Clin Oncol. 2023;41(Suppl 16; abstr TPS7074). doi:10.1200/JCO.2023.41.16 suppl.TPS7074.
   Web of Science ®Google Scholar
• Ueda Y, Uski K, Fujita J, Matsumura I, Aotsuka N, Sekiguchi N, Nakazato T, Iwasaki H, Takahara-Matsubara M, Sugimoto S, et al. Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes. Cancer Sci. 2022;113(4):1377–92. doi:10.1111/cas.15245.
   PubMed Web of Science ®Google Scholar
• Kiguchi T, Yamaguchi M, Takezako N, Miyawaki S, Masui K, Ihara Y, Hirata M, Shimofurutani N, Naoe T. Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial. Cancr Immunol Immunother. 2022;71(6):1419–30. doi:10.1007/s00262-021-03074-4.
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced s minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 2007;86(5):414–7. doi:10.1007/BF02983998.
   PubMed Web of Science ®Google Scholar
• Chung DJ, Sharma S, Rangesa M, Dewolf S, Elhanati Y, Perica K, Young JW. Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant. Blood Adv. 2022;6(5):1547–58. doi:10.1182/bloodadvances.2021005941.
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Miyashita M, Yamagishi Y, Ota S. Wilms’ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory malignant lymphoma. Leuk Lymphoma. 2022;63(7):1733–1737. doi:10.1080/10428194.2022.2038371.
   PubMed Web of Science ®Google Scholar
• Sweeney C, Vyas P. The graft-versus-leukemia effect in AML. Front Oncol. 2019;9:1217. doi:10.3389/fonc.2019.01217.
   PubMed Web of Science ®Google Scholar
• Alho A, Kim HT, Chammas MJ, Reynolds CG, Matos TR, Forcade E, Whangbo J, Nikiforow S, Culter CS, Koreth J, et al. Unbalanced recovery or regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016;127(5):646–57. doi:10.1182/blood-2015-10-672345.
   PubMed Web of Science ®Google Scholar
• Hashii Y, Sato-Miyashita E, Matumura R, Kusuki S, Yoshida H, Ohta H, Hosen N, Tsuboi A, Oji Y, Oka Y, et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemia patients with high risk relapse: successful maintenance of durable remission. Leukemia. 2012;26(3):530–2. doi:10.1038/leu.2011.226.
   PubMed Web of Science ®Google Scholar
• Maeda T, Hossen N, Fukushima K, Tsuboi A, Morimoto S, Matsui T, Sata H, Fujita J, Hasegawa K, Nishida S, et al. Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine. Blood Cancer J. 2013;3(8):e130. doi:10.1038/bcj.2013.29.
   PubMedGoogle Scholar
• Griffiths EA, Srivatava P, Matsuzaki J, Brumberger Z, Wang ES, Kocent J, Miller A, Roloff GW, Wong HY, Paluch BE, et al. NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome. Clin Cancer Res. 2018;24(5):1019–29. doi:10.1158/1078-0432.CCR-17-1792.
   PubMed Web of Science ®Google Scholar
• Holmberg-Thyden S, Dufva IH, Gabg AO, Breinholt MF, Schejbel L, Andersen MK, Kadivar M, Svane IM, Gronbak K, Hadrup SR, et al. Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial. Cancer Immunol Immunother. 2022;71(2):433–44. doi:10.1007/s00262-021-02993-6.
   PubMed Web of Science ®Google Scholar
• Aamdal E, Inderberg EM, Ellingsen EB, Rasch W, Brusvig PF, Aamdal S, Heintz K-M, Vodak D, Nakken S, Hovig E, et al. Combining a universal telomerase based cancer vaccine with ipilimumab in patients with metastatic melanoma-five-year follow up of a phase I/IIa trial. Front Immunol. 2021;12:663865. doi:10.3389/fimmu.2021.663865.
   PubMed Web of Science ®Google Scholar
• Lorentzen CL, Kjeldsen JW, Ehrnrooth E, Ansersen MH, Svane IM. Log-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab. J Immunother Cancer. 2023;11(5):e006755. doi:10.1136/jitc-2023-006755.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, Eysmans C, Richards A, Schell MJ, Fisher KJ, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015;21(4):712–20. doi:10.1158/1078-0432.CCR-14-2468.
   PubMed Web of Science ®Google Scholar
• Plantinga M, Presti VL, de Haar CG, Dunnebach E, Madrigal A, Lindemans CA, Boelens JJ, Nierkens S. Clinical grade production of Wilms’ tumor-1 loaded cord blood-derived dendritic cells to prevent relapse in pediatric AML after cord blood transplantation. Front Immunol. 2020;11:559152. doi:10.3389/fimmu.2020.559152.
   PubMed Web of Science ®Google Scholar
• Nakagawa N, Hashii Y, Kayama H, Okumura R, Nakajima H, Minagawa H, Morimoto S, Fujiki F, Nakata J, Shirakawa T, et al. An oral WT1 protein vaccination composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia. Cancer Immunol Immunoter. 2023;72(1):39–53. doi:10.1007/s00262-022-03214-4.
   PubMed Web of Science ®Google Scholar
• Xiang SD, Wilson KL, Goubier A, Heyerick A, Plebanski M. Design of peptide-based nanovaccines targeting leading antigens from gynecological cancers to induce HLA-A2.1 restricted CD8+ T cell responses. Front Immunol. 2018;9:2968. doi:10.3389/fimmu.2018.02968.
   PubMed Web of Science ®Google Scholar
• Shimizu T, Matsuzaki T, Fukuda S, Yoshioka C, Shimazaki Y, Takese S, Yamanaka K, Nakae T, Ishibashi M, Hamamoto H, et al. Ionic ligand-based transcutaneous peptide antitumor vaccine: therapeutic effect in a mouse tumor model. AAPS J. 2023;25(2):27. doi:10.1208/s12248-023-00790-w.
   PubMed Web of Science ®Google Scholar
• Kim Y-H, Tran T-A-T, Duong T-H-O, Jung S, Kim I-Y, Moon K-S, Jang W-Y, Lee H-J, Lee J-J, Jung T-Y. Feasibility of dendritic cell-based vaccine against glioblastoma by using cytoplasmic transduction peptide (CTP)-fused protein antigens combined with anti-PD1. Human Vaccine Immunother. 2020;16(11):2840–48. doi:10.1080/21645515.2020.1732165.
   PubMed Web of Science ®Google Scholar
• Pearson F, Tullett KM, Leal-Rojas IM, Haigh OL, Masterman K-A, Walpole C, Bridgeman JS, MacLaren JE, Ladell K, Miners K, et al. Human CLEC9A antibodies deliver Wilms’ tumor 1 (WT1) antigen to CD141 + dendritic cells to activate naïve and memory WT1-specific CD8 + T cells. Clin Trans Immunol. 2020;9(6):e1141. doi:10.1002/cti2.1141.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao S, Duan J, Hu Y, Gu N, Xu H, Yang X-D. Enhancement of DC-mediated anti-leukemic immunity in vitro by WT1 antigen and CpG co-encapsulated in PLGA microparticles. Protein Cell. 2013;4(12):887–889. doi:10.1007/s13238-013-3916-x.
   PubMed Web of Science ®Google Scholar
• Walters JN, Ferraro B, Duperret EK, Kraynyak KA, Chu J, Saint-Fleur A, Yan J, Levitsky H, Khan AS, Sardesai N, et al. A novel DNA vaccine platform enhances neo-antigen-like T cell responses against WT1 to break tolerance and induce anti-tumor immunity. Mol Ther. 2017;25(4):976–88. doi:10.1016/j.ymthe.2017.01.022.
   PubMed Web of Science ®Google Scholar